These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35671593)

  • 1. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
    Niu J; Bai H; Li Z; Gao Y; Zhang Y; Wang X; Yang Y; Xu Y; Geng M; Xie Z; Zhou B
    Eur J Med Chem; 2022 Aug; 238():114482. PubMed ID: 35671593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
    Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
    J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. M335, a novel small-molecule STING agonist activates the immune response and exerts antitumor effects.
    Zhao M; Fan W; Wang Y; Qiang P; Zheng Z; Shan H; Zhang M; Liu P; Wang Y; Li G; Li M; Hong L
    Eur J Med Chem; 2024 Jan; 264():116018. PubMed ID: 38091891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
    Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
    J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfonated Perylene as Three-in-One STING Agonist for Cancer Chemo-Immunotherapy.
    Zhao X; Zheng R; Zhang B; Zhao Y; Xue W; Fang Y; Huang Y; Yin M
    Angew Chem Int Ed Engl; 2024 Mar; 63(11):e202318799. PubMed ID: 38230819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinylphosphonate-based cyclic dinucleotides enhance STING-mediated cancer immunotherapy.
    Dejmek M; Brazdova A; Otava T; Polidarova MP; Klíma M; Smola M; Vavrina Z; Buděšínský M; Dračínský M; Liboska R; Boura E; Birkuš G; Nencka R
    Eur J Med Chem; 2023 Nov; 259():115685. PubMed ID: 37567057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STING, a promising target for small molecular immune modulator: A review.
    Liu Y; Lu X; Qin N; Qiao Y; Xing S; Liu W; Feng F; Liu Z; Sun H
    Eur J Med Chem; 2021 Feb; 211():113113. PubMed ID: 33360799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STING Activation and its Application in Immuno-Oncology.
    Lian Y; Duffy KJ; Yang J
    Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An updated patent review of stimulator of interferon genes agonists (2021 - present).
    Xin GF; Chen NN; Li LL; Liu XC; Che CC; Wu BD; You QD; Xu XL
    Expert Opin Ther Pat; 2024 May; 34(5):297-313. PubMed ID: 38849323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy.
    Xuan C; Hu R
    ChemMedChem; 2023 Dec; 18(23):e202300405. PubMed ID: 37794702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy.
    Zheng H; Guo B; Qiu X; Xia Y; Qu Y; Cheng L; Meng F; Zhong Z
    Bioact Mater; 2022 Oct; 16():1-11. PubMed ID: 35386324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity.
    Dane EL; Belessiotis-Richards A; Backlund C; Wang J; Hidaka K; Milling LE; Bhagchandani S; Melo MB; Wu S; Li N; Donahue N; Ni K; Ma L; Okaniwa M; Stevens MM; Alexander-Katz A; Irvine DJ
    Nat Mater; 2022 Jun; 21(6):710-720. PubMed ID: 35606429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight into the dichotomous regulation of STING activation in immunotherapy.
    Hu Z; Yang Y; Fang L; Zhou J; Zhang H
    Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):126-137. PubMed ID: 33618600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.
    Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG
    Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STING-Activating Small Molecular Therapeutics for Cancer Immunotherapy.
    Huang C; Tong T; Ren L; Wang H
    Chembiochem; 2024 Oct; 25(19):e202400255. PubMed ID: 38980259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting STING for cancer immunotherapy: From mechanisms to translation.
    Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.
    Ager CR; Boda A; Rajapakshe K; Lea ST; Di Francesco ME; Jayaprakash P; Slay RB; Morrow B; Prasad R; Dean MA; Duffy CR; Coarfa C; Jones P; Curran MA
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis and Biological Evaluation of (2',5' and 3'5'-Linked) cGAMP Analogs that Activate Stimulator of Interferon Genes (STING).
    Xie X; Liu J; Wang X
    Molecules; 2020 Nov; 25(22):. PubMed ID: 33198423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy.
    Zheng J; Mo J; Zhu T; Zhuo W; Yi Y; Hu S; Yin J; Zhang W; Zhou H; Liu Z
    Mol Cancer; 2020 Aug; 19(1):133. PubMed ID: 32854711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists.
    Shen A; Li X; Zhang Y; Ma J; Xiao R; Wang X; Song Z; Liu Z; Geng M; Zhang A; Xie Z; Ding C
    Eur J Med Chem; 2022 Nov; 241():114627. PubMed ID: 35963129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.